EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study medications were continued for 12 weeks. All patients received low-intensity counseling. (p = 0.012) Results Smoking abstinence at 24 weeks: 47.3% of the varenicline group vs. 32.5% of the placebo group (p = 0.012) Major adverse cardiovascular events: 4.0% with varenicline vs. 4.6% with placebo 47.3 % 32.5 Conclusions Among smokers admitted with an acute coronary syndrome, varenicline was effective at achieving a higher prevalence of smoking abstinence Although this study was not powered to examine safety, serious adverse events including major adverse cardiovascular events were similar between treatment groups Varenicline Placebo Eisenberg MJ, et al. Circulation 2015;Nov 9:[Epub]